KUKU

KU ScholarWorks

  • myKU
  • Email
  • Enroll & Pay
  • KU Directory
    • Login
    View Item 
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    CCL2/CCR2 chemokine signaling modulates ductal breast cancer progression by enhancing glycolysis and c-MET activation

    Thumbnail
    View/Open
    Acevedo_ku_0099D_17694_DATA_1.pdf (3.954Mb)
    Issue Date
    2021-05-31
    Author
    Acevedo, Diana Sofía
    Publisher
    University of Kansas
    Format
    214 pages
    Type
    Dissertation
    Degree Level
    Ph.D.
    Discipline
    Pathology & Laboratory Medicine
    Rights
    Copyright held by the author.
    Metadata
    Show full item record
    Abstract
    Despite therapeutic advancement, ductal carcinoma in situ (DCIS) remains the most common form of pre- invasive breast cancer diagnosed among women with 60,000 cases every year. Treatment for DCIS involves a combination of lumpectomy and radiotherapy in which 10-35% of patients experience disease recurrence that is often accompanied by invasive ductal carcinoma. By developing a molecular approach to evaluate the prognosis of DCIS we can identify biomarkers for DCIS patients capable of predicting which cases will become invasive and potentially spare women from non-necessary surgeries. The CCL2/CCR2 chemokine signaling is overexpressed in breast cancer biopsies and malignant breast cell lines. Here we demonstrated additional molecular factors by which CCL2/CCR2 might drive DCIS progression, by RPPA analysis on DCIS.com breast cancer cells we identified that CCL2 induction phosphorylated c-MET tyrosine kinase. By PLA we confirmed that CCR2 interacts with c-MET and by CO-IP we demonstrated that this interaction is potentially mediated by SRC dependent mechanisms. Additionally, global metabolomic analysis revealed that CCL2 alters glycolysis. Specifically, CCL2/CCR2 regulate glycolysis by enhancing glucose consumption, intracellular lactate, and upregulation of Hexokinase 2. In vitro studies targeting c-MET induced by CCL2 with the c-MET pharmacological Merestinib, resulted in blocked cellular migration, proliferation, survival, growth, and glycolysis in basal like breast cancer cells. By injecting SUM225 CCR2 overexpressing cells via the MIND Mammary Intraductal Injection model and dosing the animals orally with Merestinib, we demonstrated that c-MET inhibition mediated by CCL2/CCR2 resulted in decreased lesion mass, proliferation, and expression of glycolytic enzymes associated with formation of fewer invasive lesions compared to vehicle control. To investigate the effects of inhibiting c-MET pathway on metabolites involved in the glycolytic pathway in vivo, MIND model lesions were analyzed by IC-MS and showed that Merestinib blocked consumption of glycolytic intermediates. Lastly, we identified the physiological and clinical relevance of the CCR2 and c-MET receptors in normal, DCIS and IDC (invasive ductal carcinoma). By datamining analysis of TCGA data sets we found positive and significant mRNA correlations between CCR2 and c-MET. We further analyzed the protein expression in TMAs from DCIS and DCIS patient samples and identified that there was a positive and significant correlation between CCR2 and c-MET in DCIS and IDC tissues. Co-staining of CCR2 and c-MET demonstrated that co-expression of these receptors is higher in IDC tissues compared to DCIS and normal. These data indicate that CCR2 and c-MET mRNA, and protein expression have an important role in DCIS transition to IDC and that can potentially be identified as biomarkers use to predict DCIS progression. Implications: This project identifies a unique association between CCL2/CCR2 expression, c-MET activity, and enhancement of glycolysis with important implications into prognosis and potential management of DCIS progression. These associations can be considered as novel molecular targets for alternative therapeutic for DCIS patients expressing high levels of CCR2 and c-MET.
    URI
    http://hdl.handle.net/1808/31761
    Collections
    • Dissertations [4321]

    Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.


    We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.


    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    Browse

    All of KU ScholarWorksCommunities & CollectionsThis Collection

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    The University of Kansas
      Contact KU ScholarWorks
    Lawrence, KS | Maps
     
    • Academics
    • Admission
    • Alumni
    • Athletics
    • Campuses
    • Giving
    • Jobs

    The University of Kansas prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University’s programs and activities. The following person has been designated to handle inquiries regarding the non-discrimination policies: Director of the Office of Institutional Opportunity and Access, IOA@ku.edu, 1246 W. Campus Road, Room 153A, Lawrence, KS, 66045, (785)864-6414, 711 TTY.

     Contact KU
    Lawrence, KS | Maps